{"id":"mk0217-duration-of-treatment-12-months","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL3932503","moleculeType":"Small molecule","molecularWeight":"459.47"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Without publicly available detailed mechanism information for MK0217, the exact molecular target and pathway remain unclear from standard pharmaceutical databases. The drug is in Phase 3 development with a 12-month treatment duration, suggesting a chronic condition indication. Further clinical trial data would be needed to characterize its precise mechanism of action.","oneSentence":"MK0217 is an investigational compound developed by Organon that modulates a specific molecular target to treat its indicated condition.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:21:37.126Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT00480766","phase":"PHASE3","title":"A Research Study to Evaluate the Safety and Effectiveness of MK0217 to Prevent and Treat Bone Loss (0217-193)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2001-07","conditions":"Osteoporosis","enrollment":173},{"nctId":"NCT00389740","phase":"PHASE3","title":"A Comparison Study With Alendronate and Raloxifene in Postmenopausal Women With Osteoporosis (0217-189)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2001-04-02","conditions":"Osteoporosis, Postmenopausal","enrollment":400}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":30,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"MK0217, /Duration of Treatment : 12 Months","genericName":"MK0217, /Duration of Treatment : 12 Months","companyName":"Organon and Co","companyId":"organon-and-co","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}